Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
Clinical trial NCT04624204 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04624204
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-08
- Primary completion
- 2027-10-28
- Enrollment
- 672
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.